Background. Atypical haemolytic uraemic syndrome (aHUS) is a rare, life-threatening
disorder for which eculizumab is the only approved treatment. Life-long treatment is …

Background Eculizumab modifies the course of disease in patients with atypical haemolytic
uraemic syndrome (aHUS), but data evaluating whether eculizumab discontinuation is safe …

Background There are limited long-term outcome data in eculizumab-treated patients with
atypical hemolytic uremic syndrome (aHUS). We report final results from the largest …

Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disorder for which prompt
diagnosis and eculizumab treatment is indicated. The time for relapse and patients at risk for …

Objective To determine the efficacy and safety of eculizumab for patients with atypical
haemolytic uraemic syndrome (aHUS), compared with current treatment options. Design A …

Objective To describe how maintenance eculizumab sustains improved renal function in
severe atypical hemolytic uremic syndrome (aHUS). Case report A previously described 50 …

Atypical haemolytic uraemic syndrome (aHUS) is a rare and life-threatening disease caused
by complement system dysregulation leading to uncontrolled complement activation and …

Background Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS).
Guidelines discuss the importance of prompt treatment. We report a post hoc analysis …

Background Atypical haemolytic uremic syndrome (aHUS) is a rare but severe form of
thrombotic microangiopathy as a consequence of complement dysregulation. aHUS has a …

Background Eculizumab, a terminal complement inhibitor, is approved for atypical
haemolytic uraemic syndrome (aHUS) to inhibit complement-mediated thrombotic …